← All trials
NCT04773600
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 24, 2021
- Primary completion
- Nov 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Feb 26, 2021
- Last posted
- Apr 6, 2021
- Enrollment
- 650
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Arcutis, Inc.Lead sponsor
- Arcutis, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.